Baseline clinical characteristics of patients with MVP with and without VAs
| Overall population | MVP without VA | MVP with VA | P value | |
| N=610 | N=543 | N=67 | ||
| Age at surgery, years | 66 (IQR 57–73) | 66 (IQR 58–74) | 62 (IQR 51–71) | 0.002 |
| Female, n (%) | 219 (36%) | 187 (34%) | 32 (48%) | 0.032 |
| Barlow, n (%) | 287 (47%) | 243 (45%) | 44 (66%) | 0.001 |
| NYHA, n (%) | 0.231 | |||
| I | 167 (28%) | 148 (27%) | 19 (28%) | |
| II | 303 (50%) | 264 (49%) | 39 (58%) | |
| III | 130 (21%) | 121 (22%) | 9 (13%) | |
| IV | 8 (1%) | 8 (2%) | 0 (0%) | |
| Hypertension, n (%) | 256 (42%) | 225 (41%) | 31 (46%) | 0.45 |
| Diabetes, n (%) | 17 (3%) | 15 (3%) | 2 (3%) | 0.917 |
| Creatinine, mmol/L | 85 (IQR 74–97) | 86 (IQR 76–98) | 77 (IQR 69–89) | 0.001 |
| eGFR, mL/min/1,73 m2 | 77 (IQR 62–90) | 76 (IQR 61–90) | 82 (IQR 71–103) | 0.009 |
| History of AF, n (%) | 201 (33%) | 185 (34%) | 16 (24%) | 0.094 |
| Concomitant CABG, n (%) | 107 (18%) | 98 (18%) | 9 (13%) | 0.351 |
AF, atrial fibrillation; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; MAZE, surgical atrial fibrillation ablation; NYHA, New York Heart Association; TVP, tricuspid valve annuloplasty; VA, ventricular arrhythmia.